We’re Heading to ISSCR 2017 Next Week – Are you? Don’t miss these great talks and activities
June 09, 2017
ISSCR’s Annual Meeting begins June 13th in Boston. The ISSCR Annual Meeting is “a place where breakthrough science, global collaboration, and researchers across the breath of the field come together. The ISSCR Annual Meeting offers the best opportunity to collaborate with leaders and peers from around the world to fully realize the promise of our field in therapies, treatments, and clinical advances.” Cell Culture Dish will be attending and blogging from the event. Please don’t miss our ISSCR related blogs over the upcoming months.
If you are attending, don’t miss these exciting talks and activities!
Interesting Talks in Each Track. Here are some examples:
Session I: Presidential Symposium: A Decade of Human iPSCs from Discovery to Clinic
Session II: Organogenesis/Making Tissues and Organs
Session III: Stem Cells and Cancer
Session IV: Chromatin and RNA Biology in Stem Cells
Session V: Stem Cells, Stress, Senescence and Aging
Session VI: Tissue Regeneration and Homeostasis
Session VII: Frontiers of Cell Therapy
Concurrent Session Topics
Direct Reprogramming and Fate Conversion
Embryonic Stem Cells
Epigenetics and Stem Cells
Epithelial Stem Cells
Ethics and Regulatory Considerations
Gene Modification and Stem Cells/Gene Editing
Germ Cell Development
Hematopoietic Stem Cells
Modeling Neurodegenerative Disease
Muscle and Mesenchymal Cells
Neural Stem Cells
New Tools for Stem Cell Research
Organogenesis and Disease Modeling
Organoids and Organogenesis
Pluripotency and iPS Cell
Reprogramming I &II
Road to the Clinic I & II
Stem Cell Niches
Stem Cells and Early Embryogenesis
Stem Cells, Stress and Aging
Tissue Engineering and Clinical Applications
Tissue Regeneration and Homeostasis
Cell Culture Dish Sponsor Activities:
BD Biosciences – Booth 518
Biological Industries– Booth 407
Driving cell therapies to market with key considerations for scale-up manufacturing, partnerships and serum-free media selection
Friday, June 16, 8:00 AM-8:30 AM – Level 2, Room 205A
Speaker: Ohad Karnieli, PhD, CEO, Atvio Biotech
In the pursuit to move cell-based therapy forward, the ability to generate a consistent quality cell product remains a challenge. This presentation will explore the challenges in cell manufacturing with a focus on serum-free media selection highlighting a high-performing culture medium – MSC NutriStem® Medium. We will also discuss key considerations for choosing the right platform, technology, and the importance of selecting the right partners in bridging the gap to better processes
For more information about Biological Industries’ Activities at ISSCR, please click here
Bio-Techne – Booth 419
Talks:Win the Race to Discovery: Innovating Stem Cell Research with Cutting-Edge Single-Cell Western and Adult Stem Cell TechnologiesFriday, June 16, 2017 | 8:00–8:30 am – Innovation Showcase, Level 2, Room 253AB
RNAScope® Technology: Visualize the cellular localization of RNA expression in stem cells with RNAScope® TechnologyFriday, June 16, 2017 | 11:30 am–12:30 pm – Level 3, Ballroom East
Poster Sessions:Efficient Differentiation of Human Pluripotent Stem Cells into Neural Progenitor CellsWednesday, June 14, 2017 | 6:30–7:30 pm – Poster # W-2041
Predicting Cell Line Variability in Cardiomyocyte Differentiation Efficiency Using Non-Invasive Multi-Analyte Luminex® AssaysThursday, June 15, 2017 | 6:00 –7:00 pm – Poster # T-2057
Corning – Booth 607
Advances in Disease Modeling
From Articlesized Reprogramming of iPS Cells to Generation of Human Kidney Organoids
Building relevant models is vital to study disease mechanisms, toxicity, and regeneration. Here we present solutions and techniques to achieve standardized reprogramming of somatic cells to iPS cells and discuss transcriptional and functional differences under defined/non-defined conditions. We’ll also present the generation of human kidney organoids from iPS cells for the study of polycystic kidney disease, a leading cause of kidney failure. These techniques enable researchers to create models to study proliferation, self-renewal, differentiation, and functionality, bringing us closer to immunocompatible Cell Therapy.
Thursday, June 15, 2017 | 11:30 a.m. – 12:30 p.m.
Level 3, Ballroom East | Lunch will be served
Development of serum-free media for mouse and human hematopoietic progenitor cell (HPC) expansion and maintenance
Friday 16 June, 11:30 am – 12:30 pm – Level 2, Room 205A
Speaker: Vanda S. Lopes, PhD, Senior Scientist
Chair: Dr. Jessie H-T Ni, PhD, Chief Scientific Officer, R&D Department
Description: Robust expansion of hematopoietic progenitor cells (HPC) ex vivo is critical to support successful therapies, but the ability to generate consistently high quality cells remains a challenge. A high performing HPC expansion medium that closely meets clinical quality requirements is an essential component to reach that goal. In this workshop we will share the development of a serum-free expansion medium for mouse HPC culture and a serum- and xeno-free formulation for human HPC expansion. The performance of the media was assessed and verified on quality expansions of mouse HPCs derived from young adult bone marrow, or human CD34+ cells isolated from cord blood.
Poster Presentation: Friday 16 June, 6:00 pm – 7:00 pm
Exhibit Hall, Poster Board F-2169
Title: Development of a xeno- and serum-free expansion medium for ex vivo expansion and maintenance of human hematopoietic stem cells
Authors: Vanda S. Lopes, Jessie Kinjo, Jessie H.-T. Ni
For more information about Irvine Scientific’s Activities at ISSCR, please click here
MilliporeSigma – Booth 307
Technologies to Engineer, Evaluate and Expand Stem Cells to Advance Innovative Therapies
Thursday June 15th, 11:30-12:30 – Location: Level 2, Room 205BC
Roche – Booth 301
Specific product categories that will be highlighted include:Liberase enzyme blends for dissociating cells from primary tissues, Cedex Bioprocess Analyzers for cell counting and metabolite monitoring, downstream proteases, and all-inclusive kits for quality control testing (mycoplasma and residual enzymes).
StemBioSys – Booth 315
StemBioSys BM-HPME®: A Novel 3-Dimensional Microenvironment to Enhance Mesenchymal Stem Cell Expansion
June 16, 8-8:30 a.m., Level 2 Room 258C
Speakers: Sy Griffey, PhD and Travis J Block, PhD
#W1208A Novel Approach for Restoring the Quantity and Quality of Elderly Human Mesenchymal Stem Cells for Autologous Cell-Based Therapies
Wednesday, June 14, 2017, from 7:30 PM to 8:30 PM – within the Poster Session I Even (Travis J Block, PhD- StemBioSys)
#F1097Cell-Produced ExtracellularMatrix Provides a Tissue-Specific Niche for Controlling the Behavior of Mesenchymal Stem Cells Derived from Bone Marrow and Adipose Tissues
Friday, June 16, 2017, from 6:00 PM to 7:00 PM within the Poster Session III Odd (Milos Marinkovic, PhD candidate, UT Health San Antonio)
Stemcell Technologies – Booth 527
Novel Solutions for iPS Cell Core FacilitiesWednesday, June 14, 09:00am – 12:00pm | Level 2, Room 253ABC
Organized by Stem Cell COREdinates.
Intestinal and Cerebral Organoids: New Tools to Study Human Development and DiseasesThursday, June 15, 11:30am – 12:30pm | Level 2, Room 253ABC
Cell culture models for studying human development have previously been limited to 2-D monolayer cultures derived from primary tissues or human pluripotent stem cells (hPSCs). Recently, the development of 3-D organoid models has enabled significant advances in developmental biology, disease modeling and patient-specific drug screening. Organoids contain progenitor cells and differentiated cell types, and can self-organize into 3-D structures that resemble their in vivo counterparts. Here, we present two of these models: intestinal and cerebral organoids.
Adult intestinal epithelial stem cells are located at the bottom of crypts of Lieberkühn. Using a combination of human and mouse intestinal organoids and in vivo fate mapping studies, we describe when, where and how cell fate, and stem cell identity are first established during development. Cerebral organoids derived from hPSCs can generate cell types and cell layers that recapitulate the complex organization of the human cortex. The derived brain tissues model early human fetal brain development and have been used to study diverse brain disorders such as microcephaly, schizophrenia and Zika virus infection.
Highly Efficient Single-Cell Human Pluripotent Stem Cell Cloning and Robust Cardiomyocyte DifferentiationFriday, June 16, 11:30am – 12:30pm | Level 2, Room 253ABC
Recent advances in gene-editing techniques have led to more accessible and cost-effective methods to produce edited human pluripotent stem cell (hPSC) lines. However, low single-cell cloning efficiency (typically < 1%) remains a major limitation of this technology. To address this challenge, we developed a novel hPSC cloning supplement, CloneR™, that yields single-cell cloning efficiencies of 20-40% in mTeSR™1 and TeSR™-E8™ across multiple matrices. Gene-edited hPSC clones can be differentiated to specific cell types for disease modeling, drug discovery, or toxicology screening purposes.
The production and processing of hPSC-derived cardiomyocytes (hPSC-CMs) is both variable and cumbersome. To overcome this, we have developed an optimized workflow for hPSC-CM-based research, including cardiomyocyte differentiation, maintenance, dissociation, freezing, and support reagents. These STEMdiff™ Cardiomyocyte products facilitate reproducible and robust production and simple processing to yield high-quality hPSC-CMs (>80% cTnT + and >1×106 hPSC-CMs/well of a 12-well plate). In summary, this tutorial will highlight hPSC gene-editing and cardiac differentiation workflows using the CloneR™ supplement and the STEMdiff™ Cardiomyocyte product line.
STEMdiff™ Hematopoietic Kit Reproducibly Generates Functional Hematopoietic Progenitor Cells from Human Pluripotent Stem Cells
Sponsored Focus Session: Tools for basic and applied research
Wednesday June 14th
Organized by: Stem Cell COREdinates, Thermo Presenter: Dr. Lise Munsie, CCRM
The use of pluripotent stem cell-derived cell types for disease modeling, drug screening and regenerative medicine is an exciting area of activity in health research. Prior to the availability of pluripotent stem cells and differentiation methods, relevant and affected primary cells were difficult to obtain and frequently only accessible post-mortem. Additionally, the recent development of CRISPR/Cas9 based genome editing methods allow the creation of isogenic (matched) disease and control lines that differ only at a specific, disease-relevant locus, or to insert reporter constructs into PSC lines such that the reporter may be used to study disease biology in relevant cell types after differentiation. Recently, CCRM has created a standard protocol for efficient genome engineering in human pluripotent stem cells (hPSC). This talk will describe our protocol, and its application to the creation of a cell line that contains a voltage-sensitive fluorescent reporter that will be used to study cardiac function and disease.
Lunch Innovation Showcase: Enabling modern PSC workflows and applications including gene editing, single cell passaging, and automation
Friday June 16th
Several practical considerations hinder the development of PSC-derived models to enable insight into disease mechanisms and provide cell models for drug discovery. In this session, Dr. William Hendriks will discuss challenges in working with patient-derived PSCs, and in the CRISPR/Cas9 editing of such lines. Patient-derived lines often demonstrate decreased survival after thawing, and the transfection, recovery, and clonal isolation of edited lines can be bottlenecks to creating disease models. Dr. Hendriks will discuss the use of StemFlex™ media in addressing these challenges when creating lines used to model dystonia-parkinsonism linked to PARK7 and DYT1 mutations.
To address the labor-intensive nature of PSC culture, and to minimize variability, Dr. Duncan Crombie will discuss the development of an automated platform to enable PSC production. Here, incorporation of StemFlex™ media has improved consistency of cell morphology, and supported more robust recovery of cells after automated passaging. Together, these advantages are contributing to a system that will support high-throughput analyses of human iPSCs and their derivatives for the study of blinding eye diseases.
Clinical-grade iPSC generated with a cGMP Sendai viral reprogramming kit
Wednesday, June 14, 7:30PM, W-2170
Effect of replacement of c-Myc with L-Myc on Sendai-based reprogramming method
Wednesday, June 14, 7:30PM, W-2123
New tools for improving the genome editing workflow in human induced pluripotent stem cell applications
Wednesday, June 14, 7:30PM, W-2140
RNA Replicon platform to enable long-lasting transient expression in primary and stem cells
Wednesday, June 14, 7:30PM, W-2170
Single-cell analysis of transcription factor expression during differentiation of PSC to cardiomyocytes using flow cytometry
Wednesday, June 14, 7:30PM, W-2038
Accelerating and synchronizing the differentiation of human pluripotent stem cell–derived neural stem cells into neurons by preventing cell proliferation
Thursday, June 15, 7:00PM, T-2072
Development of a robust, next-generation, feeder-free pluripotent stem cell medium
Thursday, June 15, 7:00PM, T-2160
Development of an improved feeder-free culture system for mouse pluripotent stem cells
Friday, June 16, 6:00PM, F-2025
Impact of passaging method on iPSC quality during early clonal establishment